• The current focus of her laboratory is on cell-intrinsic and cell-extrinsic processes underlying hematopoietic stem cell dysregulation in age-related clonal hematopoiesis and myeloid malignancies. (lls.org)
  • In this review, we aim to summarize the composition of CAR-T cell and its application in the treatment of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL), multiple myeloma (MM), and acute myeloid leukemia (AML). (hindawi.com)
  • This mechanism also applies to hematopoietic cells transformed by other HOX genes, including CDX2, which is highly expressed in a majority of acute myeloid leukemias, thus providing a molecular approach based on GSK-3 inhibitory strategies to target HOX-associated transcription in a broad spectrum of leukemias. (stanford.edu)
  • Additional sex combs-like 1 ( ASXL1 ) mutations have been described in all forms of myeloid neoplasms including chronic myelomonocytic leukemia (CMML) and associated with inferior outcomes, yet the molecular pathogenesis of ASXL1 mutations ( ASXL1 -MT) remains poorly understood. (biomedcentral.com)
  • Previously, we observed that transcription factor RUNX1 mutations ( RUNX1 -MT) coexisted with ASXL1 -MT in CMML and at myeloid blast phase of chronic myeloid leukemia. (biomedcentral.com)
  • The contribution of RUNX1 mutations in the pathogenesis of myeloid transformation in ASXL1 -mutated leukemia, however, remains unclear. (biomedcentral.com)
  • Co-expression of two mutant genes increased myeloid stem cells in animal model, suggesting that cooperation of RUNX1 and ASXL1 mutations played a critical role in leukemia transformation. (biomedcentral.com)
  • The present study demonstrated the biological and functional evidence for the critical role of RUNX1 -MT in ASXL1 -mutated leukemia in the pathogenesis of myeloid malignancies. (biomedcentral.com)
  • Her translational research interests involve the development of novel biological therapies targeting the bone marrow microenvironment for myeloid malignancies. (roswellpark.org)
  • The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and efficacy of ASTX660 when given alone and in combination with ASTX727 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML). (mayo.edu)
  • Acquired somatic variants in inherited myeloid malignancies. (bioinformatics.hu)
  • Background: Early trials of long-term lenalidomide use reported an increased incidence of second primary malignancy (SPM), including acute myeloid leukaemia and myelodysplastic syndrome. (nyu.edu)
  • Tsimberidou AM, Medina J, Cortes J, Rios A, Glisson, B, Faderl S. Kantarjian H, Garcia-Manero G. Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. (uth.edu)
  • MSCs have a lower ability to differentiate into osteoblasts but a higher ability to differentiate into adipocytes, which could be linked to myeloid malignancies ( Woods and Guezguez, 2021 ). (techscience.com)
  • DNA (cytosine-5)-methyltransferase 3A (DNMT3A)-mutated acute myeloid leukemia (AML) has a poor prognosis, but the exact mechanism is still unclear. (frontiersin.org)
  • Acute myeloid leukemia (AML) is a common, heterogeneous, and aggressive hematopoietic malignancy, characterized by apparent genetic abnormalities ( 1 ). (frontiersin.org)
  • The pathologies associated with the onset of mucositis were mainly hematological malignancies (85% and 66%) with a predominance of acute myeloid leukemias. (ajol.info)
  • I have expertise in novel therapies for acute myeloid leukemia, stem cell mobilization and homing, as well as stem cell transplantation. (rochester.edu)
  • Dr. Aaron Goodman, MD , is a haematologist and medical oncologist specialized in treating a variety of blood cancers, including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and multiple myeloma. (oslocancercluster.no)
  • Current and emerging treatments for chronic myeloid leukemia: What have we learnt from EHA Hybrid Conference 2022? (touchoncology.com)
  • This activity explores the recent data for current and emerging treatments for chronic myeloid leukemia, filmed following the EHA Hybrid Conference 2022. (touchoncology.com)
  • My aim is to broaden our understanding of the pathogenesis of haematopoietic malignancies with a focus on acute myeloid leukaemia (AML) and chronic lymphocytic leukaemia (CLL), and to exploit this knowledge for the development of new cancer therapies. (sanger.ac.uk)
  • Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia. (cdc.gov)
  • Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia. (cdc.gov)
  • Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients in Clinical Practice. (cdc.gov)
  • Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. (cdc.gov)
  • Identification of Prognostic and Susceptibility Markers in Chronic Myeloid Leukemia Using Next Generation Sequencing. (cdc.gov)
  • Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? (cdc.gov)
  • Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: a systematic review and meta-analysis. (cdc.gov)
  • TP53 codon 72 polymorphism predicts chronic myeloid leukemia susceptibility and treatment outcome. (cdc.gov)
  • Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents. (cdc.gov)
  • She is a Scholar of the Leukemia & Lymphoma Society, and past recipient of the Janet Rowley Award from the International Society for Experimental Hematology, the V Foundation V Scholar Award, American Society of Hematology Scholar Award, and the Ellison Medical Foundation New Scholar Award in Aging. (lls.org)
  • The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against blood cancer. (lls.org)
  • The LLS mission: Cure leukemia, lymphoma, Hodgkin disease and myeloma, and improve the quality of life of patients and their families. (lls.org)
  • The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest extent allowed by tax laws. (lls.org)
  • That doesn't even count all the patients with leukemia or lymphoma cured primarily by chemotherapy. (sciencebasedmedicine.org)
  • Dr. Baer was featured for her work on the Maryland Public Health where she discusses the diagnoses and treatments of leukemia, lymphoma and myeloma. (umms.org)
  • A subsequent study proven that Pim-1 transgenic mice are predisposed to the development of experimental T cell lymphoma in assistance with c-Myc and N-Myc[10]. (biongenex.com)
  • This talk will survey the use of mass cytometry for systems level characterization of cells in healthy human tissues, including blood, bone marrow, and tonsillar tissue, as well as diseases including melanoma, glioblastoma, lymphoma, leukemia, bone marrow failure and myelodysplastic syndromes, and graft vs. host disease. (uib.no)
  • Low serum levels of beta 2 microglobulin essentially indicate decreased disease activity in conditions for which beta 2 microglobulin is used as a prognostic marker ( multiple myeloma , lymphoma, leukemia ) or the absence of such a disease process. (medscape.com)
  • Beta 2 microglobulin is a component of certain panels, such as chronic lymphocytic leukemia (CLL), lymphoma, or multiple myeloma prognostic/monitoring panels. (medscape.com)
  • Maria R. Baer, MD joined the University of Maryland Marlene and Stewart Greenebaum Cancer Center as Director of Hematologic Malignancies in April 2007. (umms.org)
  • Clinical Evaluation of Massively Parallel RNA Sequencing for Detecting Recurrent Gene Fusions in Hematologic Malignancies. (cdc.gov)
  • Serum and plasma beta 2 microglobulin values have emerged as markers for the activation of the cellular immune system, as well as a tumor marker in certain hematologic malignancies. (medscape.com)
  • He has published more than 500 peer-reviewed articles in the fields of molecular pathogenesis of haematological malignancies (1986-present), molecular medicine applied to clinical medicine (1978-present) and the molecular basis of thalassemia and related haemoglobinopathies (1978-1990). (cml-foundation.org)
  • He has published more than 600 peer-reviewed articles in the fields of molecular pathogenesis of haematological diseases, molecularly targeted therapy and molecular characterization of haematological malignancies. (touchoncology.com)
  • This study aims to evaluate the safety, efficacy and duration of response of CD19 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in children with high risk, relapsed CD19+ haematological malignancies. (mycancergenome.org)
  • In addition to these basic issues concerning leukemia pathogenesis, we are devising new diagnostic procedures for detecting and monitoring leukemia patients based on molecular genetic abnormalities in the malignant cells. (stanford.edu)
  • It is noted that T cell has great potential for immunotherapy of hematological malignancies. (hindawi.com)
  • Given that B7-H3-targeted therapies have been evaluated in early clinical trials, our studies provide insights into the potential of biomarker-driven combinatorial immunotherapy targeting B7-H3 in prostate cancer, among other malignancies. (urotoday.com)
  • His research interests include immunotherapy and cellular therapy treatment for haematologic malignancies and identifying biomarkers for response to immunotherapy. (oslocancercluster.no)
  • Our research focuses on developmental pathways that regulate hematopoietic cell growth and differentiation and are disrupted in the course of neoplastic transformation, particularly in leukemias and lymphomas. (stanford.edu)
  • We provide comprehensive care through collaboration with members of the Divisions of Surgery, Radiation Oncology, Pathology, and Radiology and includes multidisciplinary tumor board conferences and coordination of care through the Memorial Hermann Cancer Center for the treatment of Acute and Chronic Leukemias, Malignant Lymphomas, and Plasma Cell Disorders (Multiple Myeloma, MGUS and Amyloid-related Disorders). (uth.edu)
  • As chemotherapy affects cell division, tumors with high growth fractions (such as acute myelogenous leukemia and the aggressive lymphomas , including Hodgkin's disease ) are more sensitive to chemotherapy, as a larger proportion of the targeted cells are undergoing cell division at any time. (wikidoc.org)
  • Malignancies with slower growth rates, such as indolent lymphomas, tend to respond to chemotherapy much more modestly. (wikidoc.org)
  • Pim-2 was similarly identified as a proviral integration site in Moloney murine leukemia virus-induced T cell lymphomas[11] and may synergize with c-Myc-induced Calcifediol lymphomagenesis[8]. (biongenex.com)
  • To evaluate the follow-up and the effectiveness of an experimental protocol of management of the mucositis in the department of hematology and pediatric oncology of the Hospital 20th August 1953 in Morocco. (ajol.info)
  • BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis). (mayo.edu)
  • Impaired neutrophil activity is an important issue in chronic lymphocytic leukemia (CLL), as it contributes to a dysfunctional immune response leading to life-threatening infections in patients. (biomedcentral.com)
  • The progression of chronic lymphocytic leukemia (CLL) is strongly associated with the modification of diverse immune cell populations to create a niche appropriate for the proliferation and survival of leukemic B cells. (biomedcentral.com)
  • The myeloproliferative neoplasms (MPNs) are a heterogeneous group of chronic hematological malignancies that are generally divided into the Philadelphia chromosome-positive (Ph-positive) MPNs, which refers to chronic myelogenous leukemia (CML) and the Philadelphia chromosome-negative (Ph-negative) MPNs. (cancernetwork.com)
  • The purpose of this study was to assess the effect of chronic inhalation exposure to mixtures of nitrous - oxide (10024972) (NO) and halothane (151677) (HT) on the reticuloendothelial malignancies in rats. (cdc.gov)
  • the other patient was a 60-year-old man who had chronic lymphocytic leukemia and in whom cerebral aspergillosis later developed and was confirmed by biopsy. (cdc.gov)
  • She has conducted and participated in numerous clinical trials in leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. (umms.org)
  • The initial diagnostic evaluation of patients with any lymphoproliferative malignancy should include a careful history and physical examination, with close attention paid to the presence of systemic B symptoms, lymph node involvement, organomegaly, and evidence of cutaneous involvement. (medscape.com)
  • Traditionally, the treatment of hematological malignancies is administrated by chemotherapy, radiotherapy, and stem cell transplantation. (hindawi.com)
  • A unique feature of this program is the designation of a permanent regular bed for the Leukemia Program in the chemotherapy unit. (uth.edu)
  • inhibitor inhibited cell proliferation when human being pancreatic malignancy cells were injected into Calcifediol nude mice without inducing any major adverse effects. (biongenex.com)
  • Therefore Pim-3 kinase may serve as a novel molecular target for developing focusing on medicines against pancreatic and other types of malignancy. (biongenex.com)
  • There are limited experimental, clinical, and epidemiologic data that pancreatic damage may result from injury caused by direct viral invasion. (cdc.gov)
  • In addition, the isolation and storage of umbilical cord blood hematopoietic stem cells have been used to rebuild the immune system for the treatment of hematological malignancies and might be promising for the dynamic equilibrium expansion of functional T cells [ 12 ]. (hindawi.com)
  • Myelofibrosis (MF) is a hematopoietic stem cell malignancy classified as a myeloproliferative neoplasm (MPN). (cancernetwork.com)
  • However, CAR-T cells can also produce some adverse events after treatment of hematological malignancies, such as cytokine release syndrome (CRS), neurotoxicity, and on-target/off-tumor toxicity, which may cause systemic immune stress inflammation, destruction of the blood-brain barrier, and even normal tissue damage. (hindawi.com)
  • In xenografts, the tumor volumes in the experimental group were significantly larger than those in the control group, and the proportion of M2 macrophages was significantly higher. (frontiersin.org)
  • Arsenite may be the predominant type of arsenic within contaminated drinking water and may be the type mainly related to the induction of individual malignancies including lung epidermis bladder and liver organ cancer tumor [1]. (researchhunt.com)
  • The state of the art in single cell tumor immunology will be discussed, including tissue collection, technical and biological quality controls, analysis of cell signaling (phospho-flow), computational analysis, and integration of different experimental and clinical data types 3 . (uib.no)
  • It is believed that the occurrence of leukemia is the result of genetic and epigenetic changes in protooncogene and tumor suppressor genes [ 8 ]. (hindawi.com)
  • Este tumor se originó espontáneamente como carcinoma del pulmón en un ratón C57BL. (bvsalud.org)
  • The study will evaluate the safety, efficacy and duration of response of the CD19 CAR T-cells in children with high risk relapsed CD19 + malignancies. (mycancergenome.org)
  • Children and young adults (age 24 years or younger) with high risk/relapsed CD19 + haematological malignancy: 1. (mycancergenome.org)
  • Since July 2014, she has been the Co-Leader of the University of Maryland Marlene and Stewart Greenebaum Cancer Center Experimental Therapeutics Program. (umms.org)
  • She previously served as Chief of the Leukemia Section of Roswell Park Cancer Institute and Professor of Medicine and Associate Professor of Molecular Pharmacology and Cancer Therapeutics at the University at Buffalo School of Medicine and Biomedical Sciences in Buffalo, New York. (umms.org)
  • The compound has been found to show promising in vitro and in vivo activities against certain B-cell malignancies [ 12 ], and has been under preclinical toxicogical development in the National Cancer Institute Experimental Therapeutics (NExT) program. (biomedcentral.com)
  • He also treats people with rare haematologic disorders using experimental therapeutics. (oslocancercluster.no)
  • He works with cancer immunology, developmental therapeutics and biomarkers, with a clinical interest in phase 1 clinical trials and genitourinary malignancies. (oslocancercluster.no)
  • In June 2007, Calin joined MD Anderson as an associate professor in Experimental Therapeutics and was promoted to professor with tenure in 2013. (mdanderson.org)
  • After having extensively worked on breast and ovarian cancer at the Experimental Therapeutics Department, he joined the Calin Laboratory as a Research Assistant II in 2016. (mdanderson.org)
  • Indeed, neutrophils are able to support leukemia progression through mechanisms that mimic the cooperation of neutrophils with healthy regulatory B cells [ 6 ]. (biomedcentral.com)
  • Adoptive cell therapy (ACT) with chimeric antigen receptor T (CAR-T) cells can restore the activity of exhausted T cell through reprogramming and is widely used in the treatment of relapsed/refractory (r/r) hematological malignancies. (hindawi.com)
  • 3) We are defining the properties of cancer stem cells that initiate and sustain the unique disease features of acute leukemias through the use of various adoptive animal models. (stanford.edu)
  • Acute lymphoblastic leukemia (ALL) is a malignant expansion of lymphoblasts in the bone marrow, blood, and extramedullary tissues [ 1 ]. (karger.com)
  • To investigate the interrelation between Treg and neutrophils in the leukemia microenvironment, we performed experiments using TCL1-injected DEREG mice with Treg depletion or RAG2KO mice with adoptively transferred TCL1 cells alone or together with Treg. (biomedcentral.com)
  • Additionally, we show that Treg depletion and IL-10 neutralization induce changes in the leukemia microenvironment, partially restoring the "healthy" phenotype of neutrophils. (biomedcentral.com)
  • Monocytic leukemia was the most common neoplasm in all three groups, occurring in 13.8 percent of the males and 9.7 percent of the females. (cdc.gov)
  • Immunosurveillance , in which transformed cells are identified and destroyed before they can establish malignancy. (massgenomics.org)
  • Finally, the fifth group comprises papers focusing on the possible link between LSD and the development of malignant changes in cells, especially in the case of leukemia. (druglibrary.net)
  • Beside basic research questions in biology (e.g. clonal competition at the level of stem cells, stem cell - niche interactions or cell migration), we specifically address topics with an explicit clinical relation (e.g. disease and treatment models of different leukemia types and other malignancies). (tu-dresden.de)
  • Her laboratory focuses on mechanisms of drug resistance in leukemia cells. (umms.org)
  • Unlike the B-ALL cells from which they came, which would rapidly cause cancers and kill experimental animals into which they were injected, the newly-made macrophages could be transplanted without harm, proving that they had lost their malignant potential. (thenakedscientists.com)
  • Finally, we studied the effects of arsenide trioxide and 5-azacitidine on the proliferation of leukemia cells and the TGF- β signaling pathway. (hindawi.com)
  • At the same time, arsenide trioxide and 5-azacitidine are associated with the inhibition of cellular proliferation of acute leukemia cells and also promote the elevated expression of TGF- β signaling pathway-linked proteins, including TGF- β , Smad2, Smad3, and Smad4. (hindawi.com)
  • RUNX1-positive leukemia cells in preclinical models. (lu.se)
  • Il s'était agi d'une étude prospective descriptive qui s'était déroulée du 15 novembre 2016 au 16 avril 2017 en deux phases : une phase 1 d'état des lieux et une phase 2 d'évaluation du protocole expérimental. (ajol.info)
  • It was a prospective descriptive study that took place from November 15, 2016 to April 16, 2017 in two phases: a phase 1 inventory and a phase 2 evaluation of the experimental protocol. (ajol.info)
  • We employ a variety of experimental systems for our studies ranging from molecular biology to transgenic and knockout mice. (stanford.edu)
  • In recent years, with the increased understanding of the molecular genetic basis of these malignancies, immune-targeted therapy has become a new possibility for the treatment of hematological malignancies. (hindawi.com)
  • The last decade has witnessed great advances in our understanding of the genetic and biological basis of childhood acute lymphoblastic leukemia (ALL), the development of experimental models to probe mechanisms and evaluate new therapies, and the development of more efficacious treatment stratification. (haematologica.org)
  • Several lines of evidence indicate that there is a genetic predisposition to acute lymphoblastic leukemia (ALL), at least in a subset of cases. (haematologica.org)
  • Acute leukemias induced by MLL chimeric oncoproteins are among the subset of cancers distinguished by a paradoxical dependence on GSK-3 kinase activity for sustained proliferation. (stanford.edu)
  • T-cell acute lymphoblastic leukemia (T-ALL) is an uncommon, aggressive malignancy that rarely presents in the skin and is generally not considered as part of the differential diagnosis by dermatologists and dermatopathologists. (karger.com)
  • His research focuses on understanding the role of non-coding RNAs including miRNAs and lncRNAs in B cell malignancies. (mdanderson.org)
  • Over the last few decades, the treatment of hematological malignancies has gained tremendous headway, but these diseases still have high morbidity and mortality [ 1 - 3 ]. (hindawi.com)
  • Dr Saglio is co-ordinator of the PhD programme in Molecular Medicine and Experimental Therapy at the University of Turin, past-president of the Italian Society of Experimental Haematology (SIES) and general secretary of the IACRLRD (International Association for Comparative Research on Leukemia and Related Diseases). (cml-foundation.org)
  • Familial predisposition specific to leukemia is uncommon but has resulted in the identification of predisposing non-silent variants that are also observed in sporadic ALL cases, including TP53 germline mutations and low hypodiploid B-ALL, ETV6 variants and hyperdiploid ALL, and PAX5 mutations and B-ALL with dicentric/isochromosome 9. (haematologica.org)
  • It provides easy access for patients with acute leukemia either by direct referral or hospital-to-hospital transference from other institutions. (uth.edu)
  • We are committed to be a resource to the patients with acute leukemia in the Memorial Hermann System and in the greater Houston area. (uth.edu)
  • Our comprehensive array of programs allows us to be of service to patients with acute leukemia with specific clinical situations such as those with acute leukemia during pregnancy as well as patients with complex cardiovascular conditions. (uth.edu)
  • This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with Acute Myelogenous Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). (rochester.edu)
  • Our present research is aimed at studying the abnormal expression of GRHL2 and the association of methylation in patients with acute leukemia and its relationship with prognosis. (hindawi.com)
  • We used quantitative real-time polymerase chain reaction (qRT-PCR) for detecting the aberrant expression level of GRHL2 in 60 patients with acute leukemia and 60 normal controls. (hindawi.com)
  • At the same time, the expression level of GRHL2 in patients with acute leukemia was significantly correlated with leukocyte count, platelet count, and cytogenetic risk grouping. (hindawi.com)
  • Increased expression and methylation level of GRHL2 are closely associated with the prognosis and malignant phenotype of acute leukemia patients and play an irreplaceable role in the occurrence and development of patients with acute leukemia. (hindawi.com)
  • Dr. Eunice Wang is the Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center. (roswellpark.org)
  • Second malignancy currently requiring active therapy, except breast or prostate cancer stable on or responding to endocrine therapy. (mayo.edu)
  • New generations of treatments have successfully targeted cancer cell signaling and modulated anti-cancer immunity to significantly improve outcomes for advanced stage malignancies. (uib.no)
  • Among microRNAs that have been linked to cancer, it is the most commonly overexpressed in malignancies (PNAS 109:20047-20052, 2012). (biomedcentral.com)
  • Experimental outcomes from animal research demonstrated that K6/ODC mice provided 10 ppm arsenite in normal water for five a few months develop epidermis squamous papillomas [2]. (researchhunt.com)
  • We demonstrate here that GSK-3 maintains the MLL leukemia stem cell transcriptional program by promoting the conditional association of CREB and its coactivators TORC and CBP with homedomain protein MEIS1, a critical component of the MLL-subordinate program, which in turn facilitates HOX-mediated transcription and transformation. (stanford.edu)
  • This gene product is a bZIP protein, which was also identified as a cellular transcription factor that binds to an enhancer in the promoter of the T cell leukemia virus type 1 promoter. (cancerindex.org)
  • T cell immune protection plays a pivotal role in the treatment of patients with hematological malignancies. (hindawi.com)
  • However, T cell exhaustion might lead to the possibility of immune escape of hematological malignancies. (hindawi.com)
  • This suggests that a treatment based on this approach might achieve a double benefit, nailing the malignancy and also bolstering the immune system in the process. (thenakedscientists.com)
  • Toki H, Hersh EM, Gutterman J, Haynie P, Glenn H, White RA, Rios A. Organ distribution and clearance studies of technetium-labeled corynebacterium in patients with leukemia. (uth.edu)
  • We analyzed the significant correlation between the expression level of GRHL2 with clinicopathological features and patients' prognosis in acute leukemia using the corresponding statistical methods. (hindawi.com)
  • While experimental evidence has shown that miR-155 is over-expressed in malignant tumors, the specific mechanism of action of miR-155 was unknown until recently. (biomedcentral.com)
  • Previously treated with any oral Janus Kinase inhibitor (JAKi) or other kinase inhibitors, experimental or approved. (who.int)